FDA lets Guidant widen HF (heart failure) device market
This article was originally published in Clinica
The US FDA has given Guidant the green-light to broaden the indication for its cardiac resynchronisation therapy defibrillators (CRT-Ds) for heart failure (HF), a move that allows the devices to be made available to thousands more patients.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.